These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 32422341)

  • 21. Safety of ACEi and ARB in COVID-19 management: A retrospective analysis.
    Kumar S; Nikravesh M; Chukwuemeka U; Randazzo M; Flores P; Choday P; Raja A; Aseri M; Shivang S; Chaudhuri S; Barve P
    Clin Cardiol; 2022 Jul; 45(7):759-766. PubMed ID: 35481554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19.
    Huang NX; Yuan Q; Fang F; Yan BP; Sanderson JE
    PLoS One; 2023; 18(1):e0280280. PubMed ID: 36634085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.
    Bean DM; Kraljevic Z; Searle T; Bendayan R; Kevin O; Pickles A; Folarin A; Roguski L; Noor K; Shek A; Zakeri R; Shah AM; Teo JTH; Dobson RJB
    Eur J Heart Fail; 2020 Jun; 22(6):967-974. PubMed ID: 32485082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities.
    Patoulias D; Katsimardou A; Stavropoulos K; Imprialos K; Kalogirou MS; Doumas M
    Curr Hypertens Rep; 2020 Sep; 22(11):90. PubMed ID: 32910274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blocker Use, Gastrointestinal Symptoms, and Mortality Among Patients With COVID-19.
    Tan ND; Qiu Y; Xing XB; Ghosh S; Chen MH; Mao R
    Gastroenterology; 2020 Sep; 159(3):1170-1172.e1. PubMed ID: 32422208
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of continuing the use of renin-angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis.
    Liu Q; Fu W; Zhu CJ; Ding ZH; Dong BB; Sun BQ; Chen RC
    BMC Infect Dis; 2023 Jan; 23(1):53. PubMed ID: 36694122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].
    Huang W; Li T; Ling Y; Qian ZP; Zhang YY; Huang D; Xu SB; Liu XH; Xia L; Yang Y; Lu SH; Lu HZ
    Zhonghua Nei Ke Za Zhi; 2020 Sep; 59(9):689-694. PubMed ID: 32838499
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
    Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
    J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality.
    Fernando ME; Drovandi A; Golledge J
    Syst Rev; 2021 Sep; 10(1):243. PubMed ID: 34488897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in patients with COVID-19: a systematic review and meta-analysis.
    Lo KB; Bhargav R; Salacup G; Pelayo J; Albano J; McCullough PA; Rangaswami J
    Expert Rev Cardiovasc Ther; 2020 Dec; 18(12):919-930. PubMed ID: 32945216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of ACEI/ARB drugs in patients with COVID-19 combined with diabetes mellitus: A protocol for systematic review and meta-analysis of randomized controlled trials.
    Yang Y; Liu X; Liu Y; Chen Y; Tian Y; Fu X; Zhong W; Xie C
    Medicine (Baltimore); 2020 Aug; 99(35):e21723. PubMed ID: 32871892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway.
    Felber R; New W; Riskin SI
    Cureus; 2024 Mar; 16(3):e55563. PubMed ID: 38576704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19.
    Bae DJ; Tehrani DM; Rabadia SV; Frost M; Parikh RV; Calfon-Press M; Aksoy O; Umar S; Ardehali R; Rabbani A; Bokhoor P; Nsair A; Currier J; Tobis J; Fonarow GC; Dave R; Rafique AM
    Am J Cardiol; 2020 Oct; 132():150-157. PubMed ID: 32819683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease: A Systematic Review and Meta-Analysis.
    Tleyjeh IM; Bin Abdulhak AA; Tlayjeh H; Al-Mallah MH; Sohail MR; Hassett LC; Siller-Matula JM; Kashour T
    Am J Ther; 2020 Dec; 29(1):e74-e84. PubMed ID: 33395057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.
    Usman MS; Siddiqi TJ; Khan MS; Ahmed A; Ali SS; Michos ED; Hall ME; Krasuski RA; Greene SJ; Butler J; Alkhouli M
    Am J Cardiol; 2020 Sep; 130():159-161. PubMed ID: 32624189
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis.
    Sadria M; Layton AT
    PLoS Comput Biol; 2020 Oct; 16(10):e1008235. PubMed ID: 33031368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Grover A; Oberoi M
    Eur Heart J Cardiovasc Pharmacother; 2021 Mar; 7(2):148-157. PubMed ID: 32542337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension.
    Yuan Y; Liu D; Zeng S; Wang S; Xu S; Wang Y; Yu R; Gao Y; Li H; Feng X; Zhou N; Zhao C; Gao Q
    J Infect; 2020 Nov; 81(5):816-846. PubMed ID: 32800800
    [No Abstract]   [Full Text] [Related]  

  • 39. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
    Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
    Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
    Derington CG; Cohen JB; Mohanty AF; Greene TH; Cook J; Ying J; Wei G; Herrick JS; Stevens VW; Jones BE; Wang L; Zheutlin AR; South AM; Hanff TC; Smith SM; Cooper-DeHoff RM; King JB; Alexander GC; Berlowitz DR; Ahmad FS; Penrod MJ; Hess R; Conroy MB; Fang JC; Rubin MA; Beddhu S; Cheung AK; Xian W; Weintraub WS; Bress AP
    PLoS One; 2021; 16(4):e0248080. PubMed ID: 33891615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.